FibroGen is a biotechnology business based in the US. FibroGen shares (FGEN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.38 – an increase of 11.48% over the previous week. FibroGen employs 486 staff and has a trailing 12-month revenue of around $173.8 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.38 |
|---|---|
| 52-week range | $0.30 - $2.93 |
| 50-day moving average | $0.39 |
| 200-day moving average | $1.13 |
| Wall St. target price | $0.60 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.70 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.3544 from 2024-10-15
| 1 week (2024-10-10) | 5.16% |
|---|---|
| 1 month (2024-09-17) | -20.91% |
| 3 months (2024-07-17) | -66.88% |
| 6 months (2024-04-17) | -72.09% |
| 1 year (2023-10-17) | -45.56% |
|---|---|
| 2 years (2022-10-17) | -97.90% |
| 3 years (2021-10-13) | N/A |
| 5 years (2019-10-17) | 40.51 |
| Revenue TTM | $173.8 million |
|---|---|
| Gross profit TTM | $-159,212,000 |
| Return on assets TTM | -26.55% |
| Return on equity TTM | -1015.79% |
| Profit margin | -96.84% |
| Book value | $-2.31 |
| Market Capitalization | $34.4 million |
TTM: trailing 12 months
We're not expecting FibroGen to pay a dividend over the next 12 months.
Over the last 12 months, FibroGen's shares have ranged in value from as little as $0.3011 up to $2.93. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while FibroGen's is 0.702. This would suggest that FibroGen's shares are less volatile than average (for this exchange).
FibroGen, Inc. , a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
What you need to know about investing in the leading indicator for the overall US stock market.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Read our beginner’s guide to trading options in the US.